ProfileGDS5678 / 1455972_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 95% 94% 95% 96% 95% 93% 96% 96% 97% 97% 93% 96% 95% 94% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.378895
GSM967853U87-EV human glioblastoma xenograft - Control 28.2645894
GSM967854U87-EV human glioblastoma xenograft - Control 38.571995
GSM967855U87-EV human glioblastoma xenograft - Control 48.9090196
GSM967856U87-EV human glioblastoma xenograft - Control 58.4961295
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.7030193
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.4938396
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.9448196
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 49.2092597
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 19.089197
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.9398493
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.7227996
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.6331595
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.2108994